National Institutes of Health (NIH)

Omalizumab treats multi-food allergy better than oral immunotherapy

High rate of oral immunotherapy side effects in NIH trial explains superiority of omalizumab.

Nursing for at least six months may spur beneficial gut bacteria connected to better heart health years later.

Study of CB1 receptor has implications for chronic pain treatment.

The proposed approach is expected to save more than $65 million annually.

NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions.

Criteria may help guide treatment of dermatitis.

Lassa fever is a viral hemorrhagic disease that can be fatal and that causes permanent hearing loss.

NIH-funded study supports use of adenotonsillectomy in this at-risk patient group.

Preclinical study in rodents suggests that uric acid is ready for human clinical testing.

NIH-funded study uses cutting-edge imaging techniques to reconstruct features underlying learning and memory in the mouse brain.